Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/60bce27397b64a8289a909232d2b0ec5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:60bce27397b64a8289a909232d2b0ec5
record_format dspace
spelling oai:doaj.org-article:60bce27397b64a8289a909232d2b0ec52021-12-02T00:58:33ZOnce-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women1178-1998https://doaj.org/article/60bce27397b64a8289a909232d2b0ec52008-09-01T00:00:00Zhttps://www.dovepress.com/once-yearly-zoledronic-acid-in-the-prevention-of-osteoporotic-bone-fra-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonateIrene LambrinoudakiSophia VlachouFotini GalapiDimitra PapadimitriouK PapadiasDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 445-451 (2008)
institution DOAJ
collection DOAJ
language EN
topic Geriatrics
RC952-954.6
spellingShingle Geriatrics
RC952-954.6
Irene Lambrinoudaki
Sophia Vlachou
Fotini Galapi
Dimitra Papadimitriou
K Papadias
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
description Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate
format article
author Irene Lambrinoudaki
Sophia Vlachou
Fotini Galapi
Dimitra Papadimitriou
K Papadias
author_facet Irene Lambrinoudaki
Sophia Vlachou
Fotini Galapi
Dimitra Papadimitriou
K Papadias
author_sort Irene Lambrinoudaki
title Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
title_short Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
title_full Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
title_fullStr Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
title_full_unstemmed Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
title_sort once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/60bce27397b64a8289a909232d2b0ec5
work_keys_str_mv AT irenelambrinoudaki onceyearlyzoledronicacidinthepreventionofosteoporoticbonefracturesinpostmenopausalwomen
AT sophiavlachou onceyearlyzoledronicacidinthepreventionofosteoporoticbonefracturesinpostmenopausalwomen
AT fotinigalapi onceyearlyzoledronicacidinthepreventionofosteoporoticbonefracturesinpostmenopausalwomen
AT dimitrapapadimitriou onceyearlyzoledronicacidinthepreventionofosteoporoticbonefracturesinpostmenopausalwomen
AT kpapadias onceyearlyzoledronicacidinthepreventionofosteoporoticbonefracturesinpostmenopausalwomen
_version_ 1718403386336870400

Ejemplares similares